Nasal Delivery Redefines Immunity: Fighting Melanoma Brain Metastases with a Cancer Nanovaccine

Introduction: Despite advancements with immune checkpoint inhibitors for metastatic melanoma, their benefits are limited to a small percentage of patients, with many experiencing immune-mediated side effects or disease relapse [1]. These challenges stem from tumor-driven immunosuppression and poor T cell infiltration [2]. To overcome these barriers, we developed a precision nanovaccine (NV) targeting dendritic cells (DC). This strategy aims to enhance melanoma-immune cell interactions and broaden the range of targeted immune cells in a site-specific manner, offering a novel approach to improve outcomes.